Uncategorized

Bioheart, together with its holding subsidiary Angiocare announces the clinical result for Iberis-HTN at China Interventional Therapeutics 2023.

ARUP Laboratories announced that the U.S. Food and Drug Administration has approved AAV5 DetectCDx™ as a companion diagnostic to aid in the selection of adult patients eligible for treatment with ROCTAVIAN™.

Intensity Therapeutics, Inc. announced the pricing of its upsized initial public offering of 3,900,000 shares of common stock at a public offering price of $5.00 per share.

SK bioscience announced positive results from its Phase II clinical trials in infants of its 21-valent pneumococcal conjugate vaccine candidate, ‘GBP410’, evaluating its safety and immunogenicity.

Spexis AG, a clinical-stage biopharmaceutical company focused on rare diseases and oncology, announced that it has engaged Maxim Group LLC as a financial advisor to assist in the evaluation of strategic alternatives and fundraising opportunities.

Black Diamond Therapeutics, Inc. announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a public offering price of $5.00 per share.

POXEL SA announces that the Autorité des Marchés Financiers approved a Prospectus for the admission of new shares of the Company that have been and may further be issued upon exercise of bonds redeemable in shares or bonds redeemable in new or existing ordinary shares that already been issued or that may further be issued

Industry groups and the HHS argued the ruling against race-conscious admissions policies could roll back gains in the number of minority physicians and ultimately hurt health outcomes.

Epic is DAX Express’ first native integration, though a Nuance spokesperson stressed the clinical documentation capability remains EHR agnostic.

The multi-state bust that targeted 78 individuals represents “one of the largest healthcare fraud schemes ever prosecuted by the Justice Department,” Attorney General Merrick Garland said.